Orili 200 Tablet 1 Strip

Orili is indicated for the management of moderate to severe pain associated with endometriosis.

1. Pregnancy should be excluded before starting treatment with Elagolix, and Elagolix should be started within 7 days from the onset of menses.
2. Initial treatment with Elagolix 150 mg: 150 mg once daily up to 24 months. But in case of moderate hepatic impairment, up to 6 months.
3. Initial treatment with Elagolix 200 mg: 200 mg twice daily up to 6 months (with coexisting dyspareunia). Treatment with Elagolix 200 mg should not exceed 6 months as it may decrease bone mineral density (BMD).
4. In moderate to severe hepatic impairment: Elagolix 200 mg is not recommended.
5. Use in children and adolescents: <18 years not established.

With medicine: May potentiate P-gp substrates (e.g. digoxin), CYP2C19 substrates (e.g. omeprazole; limit doses to <40 mg daily). May antagonize CYP3A substrates. Antagonizes oral midazolam and rosuvastatin; consider increasing their doses. May be antagonized by CYP3A inducers. Reduced efficacy with estrogen-containing contraceptives.

With food and others: No known food interaction.

It is contraindicated in pregnant women because exposure to Elagolix early in pregnancy may increase the risk of early pregnancy loss. With known osteoporosis, it can increase the risk of further bone loss. It is also contraindicated for severe hepatic impairment and with concomitant use of strong organic anion transporting polypeptide OATP1B1 inhibitors (e.g., cyclosporine and gemfibrozil).

Common: The most common side effects include hot flushes, night sweats, headache, nausea, amenorrhea, arthralgia, mood changes & bone loss. Rare: Insomnia, anxiety & elevated hepatic transaminase.

The limited human data on the use of Elagolix in pregnant women are insufficient to determine whether there is a risk for major birth defects or miscarriage. Exposure to Elagolix early in pregnancy may increase the risk of early pregnancy loss. Its use is contraindicated in pregnant women. Elagolix has to be discontinued if pregnancy occurs during treatment. There is no information on the presence of elagolix or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production.

1. Bone Loss: Dose- and duration-dependent decreases in bone mineral density (BMD) that may not be completely reversible. Assess BMD in women with additional risk factors for bone loss.
2. Reduced Ability to Recognize Pregnancy: Orili may alter menstrual bleeding, which may reduce the ability to recognize pregnancy. Perform testing if pregnancy is suspected. Discontinue if pregnancy is confirmed.
3. Suicidal Ideation and Mood Disorders: Advise patients to seek medical attention for suicidal ideation, suicidal behavior, new onset or worsening depression, anxiety, or other mood changes.
4. Hepatic Transaminase Elevations: Dose-dependent elevations in serum alanine aminotransferase (ALT). Counsel patients on signs and symptoms of liver injury.
5. Potential for Reduced Efficacy with Estrogen-Containing Contraceptives: Use non-hormonal contraception during treatment and for one week after discontinuing Orili.

Store in a cool & dry place, protect from light & moisture. Keep all medicines out of reach of children.